Buradasınız

Anasayfa » Content

CRP ile Metabolik Sendrom Arasındaki İlişki

The Association Between C - reactive protein and Metabolic Syndrome Components

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Background: Insulin resistance is associated with metabolic syndrome and is a risk factor for cardiovascular disease. C-reactive protein (CRP) is an inflammatory marker which is demonstrated as a strong predictor of future cardiovascular events. Material Method: In this study, sixty-three patients who were diagnosed with metabolic syndrome and twenty healthy controls were recruited. Fasting blood glucose, insulin and CRP levels were measured. Homeostasis Model Assessment (HOMA-IR) formula is used to evaluate insulin resistance. We investigated the relationship between insulin resistance and CRP levels and whether CRP is a metabolic syndrome criterion or not. Results: There were statistically significant differences between patients with metabolic syndrome and controls in terms of waist circumference, fasting glucose, insulin and CRP levels. In patients, we found a poor but significant relationship between fasting glucose levels and CRP (P=0.0001, r=0.3) and between HOMA-IR values and CRP (P=0.007, r=0.29). Conclusion: We concluded that CRP may have an important role in the diagnosis and follow-up of metabolic syndrome.
Bookmark/Search this post with
Abstract (Original Language): 
Giriş: İnsülin direnci metabolik sendrom ile ilişkilidir ve kardiyovasküler hastalıklar için risk faktörüdür. C-Reaktif protein (CRP) gelecekteki kardiyovasküler hastalıkların habercisi olan bir proinflamatuar belirteçdir. Biz bu çalışmada insülin direnci ile CRP düzeylerinin ilişkisini ve CRP’nin metabolik sendromda kriter olup olmayacağını araştırdık. Gereç ve Yöntem: Bu çalışmaya metabolik sendrom tanısı almış 63 hasta ile 20 sağlıklı kontrol grubu dahil edildi. Açlık kan glukoz seviyeleri, insülin ve CRP düzeyleri ölçüldü. İnsülin dirençleri (Homeostasis Model Assessment=HOMA-IR) formülü kullanılarak değerlendirildi. Bulgular: Metabolik sendromlu hasta grubu ile kontrol grubu arasında bel çevresi, açlık glukozu, insülin ve CRP değerleri arasında istatistiksel anlamlı farklılıklar vardı.Hasta grubunda açlık glukoz düzeyleri ve CRP arasında (P=0,0001, r=0,3) ve HOMA-IR ile CRP arasında (P=0,007, r=0,29) zayıf fakat anlamlı bir ilişki vardı. Sonuç: CRP’nin metabolik sendromun tanı ve takibinde önemli bir parametre olduğu sonucuna vardık.
FULL TEXT (PDF): 
PDF icon arastirmax-crp-ile-metabolik-sendrom-arasindaki-iliski.pdf
  • 3
145-148
  • Turkish

REFERENCES

References: 

1. Executive Summary of The Third Report of The National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High
Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;
285(19):2486-97.
2. Sansoy V, Ersanlı M. Koroner Kalp Hastaligi Koruma ve Tedavi Kilavuzu. Turk
Kardioloji Dernegi Ars 2002; 30:568-94.
3. Unwin N, Shaw J, Zimmet P, et al. Alberti KG. Impaired glucose tolerance and
impaire fasting glycemia: The current status on definition and intervention . Diabet
Med 2002;19(9):708-23.
4. Khaw K, Warehan N, Luben R, et al. Glycated hemoglobin, diabetes and mortality
in men in Norfolk cohort of European prospective investigation of cancer and
nutrition. BMJ 2001; 322:15-8.
5. Gotto A, Pownall H. Manual of Lipid Disorders. Baltimore, Williams and Wilkins,
1999; 18-44.
6. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with
diabetes? Reanalysis of European Diabetes Epidemiology study Group. BMJ 1998;
317:371-5.
7. Isıldak M, Guven SG, Gurlek A. Metabolik sendrom ve insulin direnci. Hacettepe
Tip Dergisi 2004; 35:96.
8. Rich SS, Bowden DW, Haffner SM et al. Identification of quantitative trait loci for
glucose homeostasis. The Insulin Resistance Atherosclerosis Study (IRAS) Family
Study. Diabetes 2004; 53:1866-75.
9. De-Frozo RA, Tobin JD, Anders R. Glucose clamp technique: a method for
quantifying insulin secretion and resistance. Am. J Physiol 1979; 237:14-223.
10. American Diabetes Association . Consensus development conference on insulin
resistance. Diabetes Care 1998; 21(2):310-4.
11. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assesment:
Insuline resistance and ß-cell function from fasting plasma glucose and insuline
concentrations in man. Diabetologia 1985; 28:412-9.
12. Matsumoto K, Miyake S, Yaro M, et al. Glucose tolerance, insulin secretion, and
insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997;
20:1562-8.
13. Haffner SM, Gonzales C, Miettiner H, et al. A prospective analysis of the HOMA
model: the Mexico City Diabetes Study. Diabetes Care 1996; 19:1138-41.
14. Nagasako S, Imamato Y, Ishikama S, et al. Efficocy of troglitazone measured by
insulin resistance index (letter). Lancet 1997;350:184.
15. Ersanlı E. Insulin direnci ve sonucları. Turk Kardioloji Dernegi Lipid Gundemi
2003; 32:1-12.
16. Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of
C-reactive protein among U.S. youth. Diabetes Care 2005; 28(4):878-8l.
17. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1895-
907.
Kural et al
148
18. Ridker PM, Rifai N, Rose L, et al. Comparison of C-Reactive Protein and low
density lipoprotein cholesterol levels in the predicton of first cardiovascular events.
N Engl J Med 2002; 347(20):1557-65.
19. Fröhlich M, Imhof A. Association between C-Reactive protein and features of the
metabolic syndrome. Diabetes Care 2000; 23:1835-9.
20. Jialal I, Deveraj S, Venugopal SK. C-Reactive Protein: Risk marker or mediator in
atherothrombosis? Hypertension 2004; 44:6-11.
21. Sjoholm A, Nyström T.Inflammation and the etiology of type 2 diabetes. Diabetes
Metab Res Rev 2006; 22:4-10.

Thank you for copying data from http://www.arastirmax.com